Virologist Voznesensky: it is too early to give recommendations on the use of a nasal vaccine
Associate Professor of the Department of Infectious Diseases Sergei Voznesensky appreciated the words of the director of the Gamaleya National Research Center for Epidemiology and Microbiology Alexander Gintsburg about the benefits of a nasal vaccine against COVID-19. This is reported by RBC.
According to Gunzburg, if vaccinated against COVID-19 are vaccinated with an additional nasal drug, they will cease to be carriers of the infection. Voznesensky said he was skeptical about this. “To date, the results of the intranasal vaccine trials have not yet been published, it has not been registered. Therefore, it is too early to give such recommendations, “he said.
The specialist believes that only after the publication of the results of the study with understandable terms and in different population groups, it will be possible to talk about the effectiveness of the nasal vaccine and explore the possibility of revaccination after” Sputnik V. ” According to him, a person after routine vaccination is able to transmit the virus to another. “As for the intranasal vaccine, when it appears, it will be very useful in the prevention of COVID-19. But it's too early to talk about this, “he stressed.
In October, the Russian Ministry of Health allowed the Gamaleya Center to conduct the second phase of clinical trials of a coronavirus vaccine in the form of a nasal spray. The director of the institution, Alexander Gintsburg, said that this vaccine would not cancel the need for routine vaccinations. The nasal drug complements it, creating another barrier to the coronavirus.